(HealthDay)—An anterior cruciate ligament (ACL) implant that offers an alternative to traditional ACL reconstruction has received marketing authorization from the U.S. Food and Drug Administration—the first approval for an ACL tear treatment in more than 30 years, the agency announced yesterday. The Bridge-Enhanced ACL Repair (BEAR) Implant received approval under the De Novo premarket review